{
    "2018-03-29": [
        [
            {
                "time": "2018-03-01",
                "original_text": "Novartis, Likely, Delayed, In, Launching, Copycat, Of, Amgen, Blockbuster",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Delayed",
                        "Amgen",
                        "Blockbuster"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-03-01",
                "original_text": "What’s, Merck’s, Valuation, in, March, 2018?",
                "features": {
                    "keywords": [
                        "Merck",
                        "Valuation",
                        "March",
                        "2018"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-03-01",
                "original_text": "Exclusive:, Penn, patient, shares, the, story, of, her, CAR-T, cell, therapy, journey",
                "features": {
                    "keywords": [
                        "Penn",
                        "CAR-T",
                        "therapy"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-01-01",
                "original_text": "How, Is, Novartis’s, Cosentyx, Positioned, after, 4Q17?",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Cosentyx",
                        "4Q17"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-01",
                "original_text": "How, Novartis’s, Ophthalmology, Business, Performed, in, 2017",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Ophthalmology",
                        "2017"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-01",
                "original_text": "The, Swiss, Stock, Market, Fell, On, Pharma, Weakness",
                "features": {
                    "keywords": [
                        "Swiss",
                        "Stock",
                        "Market",
                        "Fell",
                        "Pharma",
                        "Weakness"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "stocks"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-03-01",
                "original_text": "How, Merck, Stock, Has, Performed, Recently",
                "features": {
                    "keywords": [
                        "Merck",
                        "Stock",
                        "Performed",
                        "Recently"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-01",
                "original_text": "How, Did, Novartis’s, Affinitor,, Exjade,, and, Tafinlar+Mekinist, Perform, in, 2017?",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Affinitor",
                        "Exjade",
                        "Tafinlar+Mekinist",
                        "2017"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}